Adams K, Waters K, Sobieraj D
Addict Sci Clin Pract. 2025; 20(1):19.
PMID: 39980050
PMC: 11841166.
DOI: 10.1186/s13722-025-00548-z.
Elmati P, Waseem H, Jagirdhar G, Stewart C, Bautista A
Cureus. 2024; 16(8):e68007.
PMID: 39347136
PMC: 11429073.
DOI: 10.7759/cureus.68007.
Khan M, Nicole X, Crabtree A, Moe J, Nasmith T, Daly-Grafstein D
CMAJ. 2024; 196(31):E1066-E1075.
PMID: 39313269
PMC: 11426346.
DOI: 10.1503/cmaj.240364.
Szczesniak L, Britton S, Rn T, Sullivan R
Harm Reduct J. 2024; 21(1):114.
PMID: 38849912
PMC: 11157744.
DOI: 10.1186/s12954-024-01028-4.
Witcraft S, Johnson C, Guille C
Focus (Am Psychiatr Publ). 2024; 22(1):25-34.
PMID: 38694152
PMC: 11058912.
DOI: 10.1176/appi.focus.20230018.
Buprenorphine Induction Using Microdosing for the Management of Opioid Use Disorder in Pregnancy.
Patel N, Parilla B
AJP Rep. 2024; 14(1):e88-e90.
PMID: 38370328
PMC: 10874687.
DOI: 10.1055/a-2250-6419.
National Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder.
Cowan E, Perrone J, Bernstein S, Coupet Jr E, Fiellin D, Hawk K
Ann Emerg Med. 2023; 82(3):326-335.
PMID: 37178101
PMC: 10524880.
DOI: 10.1016/j.annemergmed.2023.03.025.
A Case Series of Spouses Undergoing Rapid Micro-Induction Technique of Buprenorphine Initiation from Methadone.
Rampetsreiter K, Salapenka I, Konakanchi J, Anders J, Sethi R
Kans J Med. 2023; 16:74-78.
PMID: 36970038
PMC: 10035645.
DOI: 10.17161/kjm.vol16.18433.
Association Between Buprenorphine Dose and the Urine "Norbuprenorphine" to "Creatinine" Ratio: Revised.
Furo H, Wiegand T, Rani M, Schwartz D, Sullivan R, Elkin P
Subst Abuse. 2023; 17:11782218231153748.
PMID: 36937705
PMC: 10014968.
DOI: 10.1177/11782218231153748.
Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
Daniulaityte R, Nahhas R, Silverstein S, Martins S, Carlson R
J Subst Use Addict Treat. 2023; 147:208973.
PMID: 36804351
PMC: 10044504.
DOI: 10.1016/j.josat.2023.208973.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.
Dowell D, Ragan K, Jones C, Baldwin G, Chou R
MMWR Recomm Rep. 2022; 71(3):1-95.
PMID: 36327391
PMC: 9639433.
DOI: 10.15585/mmwr.rr7103a1.
Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.
K K A, E J M, D M S
Addict Sci Clin Pract. 2022; 17(1):55.
PMID: 36195895
PMC: 9531395.
DOI: 10.1186/s13722-022-00336-z.
Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report.
MacAusland-Berg J, Wiebe A, Marwah R, Halpape K
Can J Pain. 2022; 6(1):135-141.
PMID: 36017357
PMC: 9397438.
DOI: 10.1080/24740527.2022.2090911.
Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
Coish R, Hardial J
J Addict Med. 2022; 17(1):114-116.
PMID: 35916416
PMC: 9897269.
DOI: 10.1097/ADM.0000000000001042.
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J, Saunders J
BMC Psychiatry. 2022; 22(1):516.
PMID: 35908052
PMC: 9338516.
DOI: 10.1186/s12888-022-04175-9.
"They say it's fentanyl, but they honestly look like Perc 30s": Initiation and use of counterfeit fentanyl pills.
Daniulaityte R, Sweeney K, Ki S, Doebbeling B, Mendoza N
Harm Reduct J. 2022; 19(1):52.
PMID: 35614447
PMC: 9131678.
DOI: 10.1186/s12954-022-00634-4.
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.
Spreen L, Dittmar E, Quirk K, Smith M
Pharmacotherapy. 2022; 42(5):411-427.
PMID: 35302671
PMC: 9310825.
DOI: 10.1002/phar.2676.
Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl.
Spadaro A, Sarker A, Hogg-Bremer W, Love J, ODonnell N, Nelson L
Clin Toxicol (Phila). 2022; 60(6):694-701.
PMID: 35119337
PMC: 10457147.
DOI: 10.1080/15563650.2022.2032730.
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.
Taylor J, Johnson S, Cruz R, Gray J, Schiff D, Bagley S
J Gen Intern Med. 2021; 36(12):3810-3819.
PMID: 34159545
PMC: 8218967.
DOI: 10.1007/s11606-021-06904-4.
Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review.
Adams K, Machnicz M, Sobieraj D
Addict Sci Clin Pract. 2021; 16(1):36.
PMID: 34103087
PMC: 8186092.
DOI: 10.1186/s13722-021-00244-8.
